volume 57, issue 4, P311-319 2017
DOI: 10.1016/j.rbre.2016.11.009
View full text
|
|
Share

Abstract: Our result suggests that the presence of anti-drug antibodies against adalimumab and infliximab as well as a higher body mass index can predict subsequent drug discontinuation in axial spondyloarthritis patients.